News
-
January 04, 2021-FDA sets PDUFA goal date of July 2, 2021-
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Biologics License Application (BLA) for...
-
December 21, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has been added to the NASDAQ...
-
December 15, 2020- Potential to be the first vaccine for the prevention of coxsackievirus B, a presumed infectious trigger in the development of type 1 diabetes and celiac disease -
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of PROVENT (PROtocol for...
-
December 08, 2020-T1Detect makes T1D screening easier and more accessible with unrestricted eligibility requirements for at-home testing and financial assistance-
New York, NY and Red Bank, NJ, December 8, 2020 – On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research, has launched a...
-
November 11, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that management will present at the Stifel Virtual...